WilmerHale Counsels Translate Bio in Initial Public Offering

Download IconDownload Print IconPrint

WilmerHale Counsels Translate Bio in Initial Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Translate Bio, Inc., a clinical-stage mRNA therapeutics company developing a new class of medicines to treat diseases caused by protein or gene dysfunction, announced on June 27, 2018 the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million. The offering closed on July 2, 2018.

The WilmerHale team counseling Translate Bio through the IPO was led by Cynthia Mazareas and included Susan Murley, Craig Hilts, Timothy Kulis and Michael Lopes.

Read Translate Bio’s press release about the IPO.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel